About Us
How our products solve a defined problem
Ophthalytics revolutionizes eye screening with advanced AI technology for accurate and efficient detection of ophthalmic conditions. By harnessing the power of AI, Ophthalytics is at the forefront of the fight against diabetic retinopathy, offering a game-changing solution that improves early detection and enables timely interventions to prevent vision loss.
Explainability
It uses the power of generalized deep learning to have the highest level of explainability.
Explainability
It uses the power of generalized deep learning to have the highest level of explainability
Speed and Accuracy
The fastest and most accurate resource for DR assessment.
Speed and Accuracy
The fastest and most accurate resource for DR assessment
Camera Agnostic
Works with any camera from 30-degree to 200-degree field of view.
Camera Agnostic
Works with any camera from 30-degree to 200-degree field of view.
User-friendly Interface
Quick and efficient evaluations of patient data.
User-friendly Interface
Quick and efficient evaluations of patient data.
Cost Savings
Saves significant costs on infrastructure upgrades, serves more patients, and improves ROI.
Cost Savings
Saves significant costs on infrastructure upgrades, serves more patients, and improves ROI.
Early Detection
Diabetic retinopathy can be detected even at very early mild stages.
Early Detection
Diabetic retinopathy can be detected even at very early mild stages.
Access to Patient Data
Users can search and retrieve existing patient DR assessments anytime.
Access to Patient Data
Users can search and retrieve existing patient DR assessments anytime.
services
Our Products
ClearView-360 combines the expertise of ophthalmologists with cutting-edge AI technology to revolutionize eye screening for conditions like diabetic retinopathy and glaucoma. This innovative solution empowers ophthalmologists by providing AI-assisted analysis of retinal images, enabling accurate and efficient diagnosis. By harnessing the power of AI as a valuable tool in the diagnostic process, ClearView-360 enhances the capabilities of ophthalmologists, leading to improved detection and management of diabetic retinopathy, ultimately benefiting patients with more precise and timely interventions while opening up new revenue streams for physicians.
Ophthal-360 is an innovative fully-automated AI-powered solution that combines cutting-edge technology and expert algorithms to revolutionize eye screening, specifically targeting conditions like diabetic retinopathy. This comprehensive product offers precise and efficient automated diagnostic capabilities, utilizing AI to analyze retinal images and detect early signs of diabetic retinopathy, empowering healthcare professionals to provide timely interventions and prevent vision loss in patients. With Ophthal-360, Ophthalytics leads the way in advancing AI eye screening for diabetic retinopathy, enhancing patient care and outcomes. *currently being reviewed for FDA clearance
Our Mission
It is our vision to save visions, and we have already launched our program, free of charge, in underserved rural communities in Asia. Committed to reaching underserved communities, we have deployed our autonomous AI eye-screening service, Ophthal-360, in impoverished and rural areas of Pakistan, providing free-of-charge screenings for individuals in need. By leveraging advanced AI technology, Ophthalytics aims to bridge the gap in access to eye care, particularly for conditions like diabetic retinopathy, ultimately improving the lives of those who are most vulnerable and ensuring equitable access to high-quality eye health services.
See how Ophthalytics can help you or your organization
Ophthalytics is proud to be a member of the prestigious NVIDIA Inception Program, a leading platform that nurtures and supports innovative startups in the field of AI and machine learning. As part of this program, Ophthalytics leverages NVIDIA’s cutting-edge technologies and resources to advance the development of its AI-driven solutions for eye screening and diagnosis. This collaboration enables Ophthalytics to stay at the forefront of AI and machine learning advancements, enhancing its capabilities in delivering state-of-the-art solutions for ophthalmic care. We take pride in our graduation from the Creative Destruction Lab program, which is a testament to our unwavering commitment to innovation and growth. Additionally, we are deeply honored to have received support from the AWS Health Equity Initiative, where we actively contribute to advancing health equity in eye care.
Subscribe
Stay With Us
To get in touch with us, you may reach out via email. Our team of experts will respond to your inquiry promptly.